Low risk prostate cancer treatment management (Stage 1 and 2A):
- Active Surveillance
- Prostatectomy
- External beam radiotherapy alone
- Brachytherapy
- Expectant Management
Intermediate risk prostate cancer treatment management (Stage 2B and 2C):
- Neoadjuvant Androgen Deprivation Therapy (ADT) and radical external beam radiotherapy (undergo ADT for 2-8 months first and then radiotherapy or together with radiotherapy)
- Dose-escalated conformal external beam (3D) radiotherapy
- Prostatectomy
- ADT as primary treatment if contraindication to radiotherapy and prostatectomy
- Expectant Management
- Observation (for patients with significant morbidity or poor life expectancy)
- Neoadjuvant ADT and external beam radiotherapy (including elective treatment of pelvic lymph nodes) PLUS 2 years adjuvant hormone treatment
- Prostatectomy (for highly selected patients with low volume disease; not suggested for patients with prostate cancer stage 3B and 4) Post operative radiotherapy and/or Androgen Deprivation Therapy (ADT) may be required
- Androgen Deprivation Therapy (ADT) as primary treatment in very high risk patients with low chance of cure
- Active Surveillance(for patients with significant morbidity or poor life expectancy)
No comments:
Post a Comment